Treatment News : Ugandans Starting HIV Treatment Early Fare Very Well

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » August 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

August 14, 2014

Ugandans Starting HIV Treatment Early Fare Very Well

Ugandans with HIV who begin treatment with higher CD4 counts can do quite well on therapy, countering beliefs that guidelines calling for earlier treatment may not play out well in practice, aidsmap reports. Publishing their findings in the journal AIDS, researchers conducted a prospective, open-label study of 197 asymptomatic, treatment-naive adults with HIV who had CD4 counts above 350 (the median was 564).

The participants were treated with tenofovir, emtricitabine and efavirenz, which are the components of Atripla. For those who could not tolerate efavirenz, that med was substituted with ritonavir-boosted lopinavir (Kaletra).

After 48 weeks, 98 percent of the participants were retained in the trial. The rate of full viral suppression was 96 percent at 24 weeks and 97 percent at 48 weeks. At 98 percent of their clinic visits, participants reported taking all their antiretroviral doses.

To read the aidsmap story, click here.

Search: Uganda, HIV, early treatment, high CD4 count, aidsmap, tenofovir, emtricitabine, efavirenz, Atripla, ritonavir, lopinavir, Kaletra.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.